Form 4: Heron Therapeutics CEO Acquires Shares Through Stock Unit Vesting
SEC Form 4 Filing
Heron Therapeutics CEO, Craig Collard, acquired 13,797 shares of common stock through the vesting of restricted stock units on January 19, 2025.
Summary
- Craig Collard, CEO of Heron Therapeutics, acquired 13,797 shares of common stock on January 19, 2025.
- The acquisition resulted from the vesting of restricted stock units.
- These restricted stock units vest in 16 equal quarterly installments, beginning one quarter after the grant date of January 19, 2024.
- Collard now directly owns 314,867 shares of common stock, which includes 10,683 shares acquired through the Employee Stock Purchase Plan on October 31, 2024.
- Additionally, Collard holds 165,562 restricted stock units.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction related to executive compensation. The increase in share ownership by the CEO is a positive sign, but it is not a major event that would significantly impact the company's valuation.
Positives
- The vesting of restricted stock units indicates a continued alignment of the CEO's interests with those of the shareholders.
- The increase in share ownership by the CEO could be seen as a positive sign of confidence in the company's future performance.
Industry Context
This is a routine filing related to executive compensation and is common practice for publicly traded companies. It reflects the standard vesting schedule of stock-based compensation.
Comparison to Industry Standards
- Stock-based compensation is a common practice across the pharmaceutical and biotech industries, with vesting schedules typically ranging from 3 to 5 years.
- The vesting schedule of 16 equal quarterly installments is a fairly standard approach to incentivizing long-term performance.
- Many companies in the sector, such as Amgen, Gilead Sciences, and Regeneron, use similar stock-based compensation plans for their executives.
Stakeholder Impact
- The increase in the CEO's share ownership could be viewed positively by shareholders, as it aligns management's interests with their own.
Key Dates
| Date | Description |
|---|---|
| 01/19/2024 | Grant date of the restricted stock units that vest quarterly. |
| 10/31/2024 | Date of acquisition of 10,683 shares through the Employee Stock Purchase Plan. |
| 01/19/2025 | Date of the transaction where 13,797 shares were acquired through vesting of restricted stock units. |
| 01/22/2025 | Date the Form 4 was signed. |
Keywords
Heron Therapeutics, Craig Collard, stock acquisition, restricted stock units, insider trading, executive compensation, share ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.